Jaguar Gene Therapy Presents Preclinical Data of JAG101 in Type 1 Galactosemia at American Society of Gene and Cell Therapy 25th Annual Meeting

AKE FOREST, Ill., May 16, 2022 – Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced results of two preclinical studies of JAG101 in two different animal models of Type 1 galactosemia. Results showed that low and high doses of intravenous JAG101 given as a one-time gene replacement therapy reduced levels of toxic metabolites in brain and liver tissues and increased GALT enzyme expression and activity in tissues relevant to long-term outcomes in Type 1 galactosemia.

Jaguar Gene Therapy Announces Preclinical Data Presentations at Upcoming American Society of Gene and Cell Therapy 25th Annual Meeting

LAKE FOREST, Ill., May 2, 2022 – Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced two abstracts related to its JAG101 Type 1 galactosemia program will be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, which is taking place at the Walter E. Washington Convention Center in Washington, D.C., from May 16-19.

Jaguar Gene Therapy Announces Target Genes for Initial Pipeline Programs in Severe Genetic Diseases

LAKE FOREST, Ill., Dec. 14, 2021 – Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for sizeable patient populations suffering from severe genetic diseases, today announced additional details, including target genes, for its initial preclinical pipeline programs: JAG101 for Type 1 galactosemia; JAG201 for a genetic cause of autism spectrum disorder (ASD) and Phelan-McDermid syndrome and other severe neurodevelopmental disorders with a SHANK3 mutation or deletion; and JAG301 for Type 1 diabetes.

Jaguar Gene Therapy Announces State-of-the-Art Gene Therapy Commercial Manufacturing Facility in North Carolina

LAKE FOREST, Ill., Oct. 26, 2021 – Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for larger patient populations suffering from severe genetic diseases, today announced plans for a commercial manufacturing facility in Durham, North Carolina.

Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management

LAKE FOREST, Ill., April 13, 2021 – Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, today announced it has closed a $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management.

Jaguar Gene Therapy Launches with Mission to Accelerate Breakthroughs in Gene Therapy for Patients Suffering from Severe Genetic Diseases

LAKE FOREST, Ill. (Feb. 25, 2021) – Jaguar Gene Therapy launched today after being in stealth mode for the past year and is uniquely positioned to accelerate gene therapy development. Led by the former AveXis leadership and resourced by Deerfield Management